Zacks: Brokerages Anticipate Fibrocell Science Inc (FCSC) Will Announce Earnings of -$0.38 Per Share

Brokerages forecast that Fibrocell Science Inc (NASDAQ:FCSC) will report earnings of ($0.38) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Fibrocell Science’s earnings. The highest EPS estimate is ($0.23) and the lowest is ($0.52). Fibrocell Science posted earnings per share of ($0.33) in the same quarter last year, which suggests a negative year over year growth rate of 15.2%. The business is expected to announce its next earnings results on Thursday, March 8th.

According to Zacks, analysts expect that Fibrocell Science will report full year earnings of ($2.30) per share for the current financial year, with EPS estimates ranging from ($2.58) to ($2.02). For the next year, analysts anticipate that the firm will post earnings of ($1.13) per share, with EPS estimates ranging from ($1.23) to ($1.02). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Fibrocell Science.

Several research firms have commented on FCSC. Zacks Investment Research raised shares of Fibrocell Science from a “sell” rating to a “hold” rating in a research note on Friday, September 22nd. HC Wainwright reissued a “buy” rating and set a $5.70 price target on shares of Fibrocell Science in a research note on Friday, September 15th. Canaccord Genuity reissued a “buy” rating and set a $7.00 price target (up from $3.00) on shares of Fibrocell Science in a research note on Monday, September 11th. Finally, ValuEngine downgraded shares of Fibrocell Science from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $5.21.

In other news, major shareholder Randal J. Kirk bought 2,727,273 shares of the firm’s stock in a transaction that occurred on Monday, December 11th. The shares were bought at an average cost of $0.77 per share, with a total value of $2,100,000.21. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.10% of the stock is owned by insiders.

An institutional investor recently raised its position in Fibrocell Science stock. Parametric Portfolio Associates LLC grew its holdings in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 264.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 48,259 shares of the company’s stock after purchasing an additional 35,000 shares during the quarter. Parametric Portfolio Associates LLC owned approximately 0.33% of Fibrocell Science worth $194,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 55.67% of the company’s stock.

Fibrocell Science (NASDAQ FCSC) traded down $0.05 during mid-day trading on Thursday, hitting $0.69. 1,338,100 shares of the company’s stock traded hands, compared to its average volume of 2,105,500. The stock has a market capitalization of $15.45, a P/E ratio of -0.38 and a beta of 0.40. Fibrocell Science has a 52-week low of $0.61 and a 52-week high of $4.64.

ILLEGAL ACTIVITY WARNING: This report was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/01/04/zacks-brokerages-anticipate-fibrocell-science-inc-fcsc-will-announce-earnings-of-0-38-per-share.html.

Fibrocell Science Company Profile

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Get a free copy of the Zacks research report on Fibrocell Science (FCSC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fibrocell Science (NASDAQ:FCSC)

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply